BeOne Medicines Ltd.
BeOne Medicines Ltd. (BEIGF): 10 pipeline candidates · 1 clinical trial. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
10 candidates
N/A
N/A
A transparent, data-derived signal for BeOne Medicines Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$29.6B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| anti-diarrheal agent | Phase 1 |
| bat1706 | Phase 3 |
| bg-60366 | Phase 1 |
| bg-71332 | Phase 1 |
| bgb-26808 | Phase 1 |
| bgb-b2033 | Phase 1 |
| hypomethylation agent | Phase 1 |
| lenvatinib | Phase 3 |
| sitravatinib | Phase 3 |
| zanidatamab | Phase 3 |
Frequently asked questions
How many drug candidates are in BeOne Medicines Ltd.'s pipeline?
BeOne Medicines Ltd. (BEIGF) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BeOne Medicines Ltd.'s lead drug candidate?
BeOne Medicines Ltd.'s most advanced tracked candidate is anti-diarrheal agent (Phase 1) for Advanced Solid Tumor.
What is BeOne Medicines Ltd.'s market capitalization?
BeOne Medicines Ltd.'s market capitalization is approximately $29.6B.
Who is the CEO of BeOne Medicines Ltd.?
Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. (BEIGF).
Get the full picture on BeOne Medicines Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.